SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
AUTL

Autolus Therapeutics plc (NASDAQ:AUTL)

GB · Delayed Price · Currency is USD
Healthcare · Biotechnology
$0.91-$0.07 (-7.38%)
 
Market cap
$242M
Insider Score
Health Score
Analyst consensus
Listed since
Jun 22, 2018
Market Cap$241.65M-26.8%
Revenue (ttm)$137.40M+168.7%
Net Income-$256.00M-13.9%
EPS-$0.97-15.5%
Shares Out266.34M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,898,442
Open$0.96
Previous Close$0.98
Day's Range$0.90 - $0.98
52-Week Range$0.90 - $2.58
Beta2.35
AnalystsBuy
Price Target$8.87(+877.63%)
Earnings DateMar 10, 2027

About AUTL

Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.

Address
The MediaWorks, London, GL, W12 7FP, GB
Market Cap
242 million
Employees
752
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$15.68K
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Financial Health Score
Weak
From AUTL’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
-7.38%
5 Days
-21.78%
1 Month
-42.58%
6 Months
-46.63%
1 Year
-26.83%

$AUTL stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in AUTL holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by AUTL's directors and management

Net Shares Purchased by Insiders−7k−4k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

AUTL Estimated quarterly lobbying spending

Source: U.S. Senate LDA

AUTL Revenue by Segment or Geography

$41.34MTotal
Product revenue, net$41.24M99.76%
Other income, net$99.00K0.24%

As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)

U.S. Patents

New AUTL patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to AUTL from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in AUTL

IBBiShares Biotechnology ETF$1.21M
MOONDirexion Moonshot Innovators ETF$394.92K
GWXState Street SPDR S&P International Small Cap ETF$102.87K
QQQSInvesco NASDAQ Future Gen 200 ETF$50.45K
APIEActivePassive International Equity ETF$28.82K
IBBQInvesco Nasdaq Biotechnology ETF$16.46K

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from AUTL’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
72

News check: Commercial progress evident with AUCATZYL revenue generation and positive clinical data from CARLYSLE trial supporting therapeutic validation.

Recent Insider Activity

Buys
0
Sells
1
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

+0.0 since Sep 4
0255075100Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 43.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Sep 4Sep 19Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

MOONDirexion Moonshot Innovators ETF2.00%
QQQSInvesco NASDAQ Future Gen 200 ETF0.30%
CANCTema Oncology ETF0.16%
IBBQInvesco Nasdaq Biotechnology ETF0.02%
IBBiShares Biotechnology ETF0.01%
BIBProShares Ultra Nasdaq Biotechnology0.01%
APIEActivePassive International Equity ETF0.00%

Weight is the stock’s share of each fund’s holdings.